Global cancer statistics in the year 2000

Lancet Oncology

Volumn 2, Issue 9, 2001, Pages 533-543

  Parkin, D Maxwell ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FORECASTING; HEALTH; HUMAN; NEOPLASM; REVIEW;

FORECASTING; HUMANS; NEOPLASMS; WORLD HEALTH;

EID: 0035467993     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00486-7     Document Type: Review

References (59)

1. United Nations Development Programme (UNDP). Human development report 2000. Oxford: Oxford University Press, 2000.
2. United Nations Environment Programme. Global environment outlook 1997. New York: Oxford University Press, 1997.
3. World Health Organisation. World Health Report 2000. WHO, Geneva, 2000.
4. The World Bank. World Development Report 1993. Investing in health. New York: Oxford University Press, 1993.
5. Brown L, French H, Flavin C, et al, Eds. State of the world 2000. The Worldwatch Institute, New York: WW Norton, 2001.
6. Mackay J. The state of health atlas. 1993;Simon and Schuster, London.
7. Pisani F, Bray F, Parkin DM. Estimates of worldwide prevalence of cancer for twenty five sites in the adult population. Int J Cancer (in press).
8. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of twenty-five major cancers in 1990. Int J Cancer. 80:1991;827-841.
9. Pisani P., Parkin D.M., Bray F.I., Ferlay J. Estimates of the worldwide mortality from twenty-five major cancers in 1990: implications for prevention, and projections of future burden. Int J Cancer. 83:1999;18-29.
10. Ries LA, Kosary CL, Hankey BF, et al, Eds. SEER cancer statistics review 1973-1994. NIH Publication No 97-2789, Bethesda: US Department of Health and Human Services, NCI, 1997.
11. Berrino F, Capocaccia R Est've J, Gatta J, et al, Eds. Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Scientific Publication No. 151, Lyon: IARC Press, 1999.
12. Sankaranarayanan R, Black RJ, Parkin DM. Cancer survival in developing countries, IARC Scientific Publication No 145, Lyon: IARC Press, 1998.
13. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No 5. Lyon: IARC Press, 2001.
14. United Nations. World Population Prospects: the 1998 revision. Volume 1 comprehensive tables, New York: United Nations, 1999.
15. Hakulinen T., Hansluwka, Lopez A.D., Nakada T. Global and regional mortality patterns by cause of death in 1980. Int J Epidemiol. 15:1986;227-233.
16. Bulatao R.A., Stevens P.W. Estimates and projections of mortality by cause: a global overview, 1970-2015. Jamieson D.T., Mosley W.H. Evolving health sector priorities in developing countries. 1989;Population, Health and Nutrition Division, The World Bank, Washington.
17. Murray C.J.L., Lopez A. The global burden of disease. 1996;Harvard University Press, Cambridge.
18. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 349:1997;1436-1442.
19. Preston H.S. Mortality patterns in national populations. 1976;Academic Press, New York.
20. Doll R., Peto R. The causes of cancer. 1981;Oxford University Press, Oxford.
21. Parkin D.M., Pisani P., Lopez A.D., Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer. 59:1994;494-504.
22. Gilliland F.D., Samet J.M. Lung cancer. Cancer Surv. 19-20:1994;175-195.
23. Lopez-Abente G., Pollan M., de-la Iglesia P., Ruiz M. Characterization of the lung cancer epidemic in the European Union 1970. Cancer Epidemiol Biomarkers Prev. 4:1995;813-820.
24. Geddes M, Parkin DM, Khlat M, Balzi D, Buiatti E, Eds. Cancer in Italian migrants populations. IARC Scientific Publication No 123. Lyon: IARC Press, 1993.
25. Tyczynski J, Tarkowski W, Parkin DM, Zatonski W. Cancer mortality among Polish migrants to Australia. Eur J Cancer. 30A:1994;478-484.
26. Ziegler R.G., Hoover R.N., Pike M.C., et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 85:1993;1819-1827.
27. Blot W.J., Fraumeni J.F. Trends in esophageal cancer mortality among US blacks and whites. Am J Public Health. 77:1987;296-298.
28. Hermon G., Beral V. Breast cancer mortality rates are levelling off or beginning to decrease in many western countries: analysis of time trends, age - cohort and age - period models of breast cancer mortality in 20 countries. Br J Cancer. 73:1996;955-960.
29. Blanks R.G., Moss S.M., McGahan C.E., et al. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-1998: comparison of observed with predicted mortality. BMJ. 321:2000;665-669.
30. Haenszel W., Kurihara M. Studies of Japanese migrants. I Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 40:1968;43-68.
31. McMichael A.J., McCall M.G., Hartshorne J.M., Woodings T.L. Patterns of gastrointestinal cancer in European migrants to Australia: the role of dietary change. Int J Cancer. 5:1980;431-437.
32. McMichael A.J., Giles G.G. Colorectal cancer. Cancer Surv. 1920:1994;77-98.
33. Koo L.C., Mang O.W.K., Ho J.H.C. An ecological study of trends in cancer incidence and dietetary changes in Hong Kong. Nutr Cancer. 28:1997;289-301.
34. IARC Monograph on the evaluation of carcinogenic risks to humans, Vol 61. Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC Press, 1994.
35. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 13:1999;851-856.
36. World Cancer Research Fund (WCRF) Panel. Diet, nutrition and the prevention of cancer: a global perspective. Washington: World Cancer Research Fund, 1997.
37. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:1998;2049-2053.
38. Laheij R.J., Straatman H., Verbeek A.L., Jansen J.B. Mortality trend from cancer of the gastric cardia in The Netherlands, 1969-94. Int J Epidemiol. 28:1999;391-395.
39. Donato F., Boffetta P., Puoti M.A. Meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 75:1998;347-354.
40. Tanaka H., Hiyama T., Tsukuma H., et al. Prevalence of second generation antibody to hepatitis C antibody among voluntary blood donors in Osaka, Japan. Cancer Causes Control. 5:1994;409-413.
41. Parkin DM, Pisani P, Munoz N, Ferlay J. The global health burden of infection associated cancers. In: Weiss RA, Beral V, Newton R, Eds. Infections and human cancer. Vol 33 Cancer Surveys, 1999.
42. Parkin D.M., Ohshima H., Srivatanakul P., Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev. 2:1993;537-544.
43. Shibata A., Whittemore A. Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate. 32:1997;65-72.
44. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 85:2000;60-67.
45. Legler J.M., Feuer E.J., Potosky A.L., et al. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 9:1998;519-527.
46. Mercer S.L., Goel V., Levy I.G., et al. Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions. Can J Public Health. 88:1997;327-332.
47. Chamberlain J., Melia J., Moss S., Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess. 1:1997;1-53.
48. Grosclaude P., Menegoz F., Schaffer P., et al. Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990. Prog Urol. 7:1997;647-654.
49. Threlfall T.J., English D.R., Rouse I.L. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust. 169:1998;21-24.
50. Post P.N., Kil P.J., Crommelin M.A., et al. Trends in incidence and mortality rates for prostate cancer before and after prostatespecific antigen introduction. A registry-based study in southeastern Netherlands, 1971-95. Eur J Cancer. 34:1998;705-709.
51. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 91:1999;1017-1024.
52. Feuer E.J., Merrill R.M., Hankey B.F. Cancer surveillance series: interpreting trends in prostate cancer, part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 91:1999;1025-1032.
53. Etzioni R., Legler J.M., Feuer E.J., et al. Cancer surveillance series: interpreting trends in prostate cancer, part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 91:1999;1033-1039.
54. IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 64, human papillomavirus. IARC, Lyon, France (1995).
55. Walboomers J.M.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;39-43.
56. Herrero R, Munoz N, Lazcano E, et al. HPV international prevalence surveys in general populations. 18th International Papillomavisus Conference, Barcelona, 2000: (abstr 054).
57. Parkin D.M., Pisani P., Ferlay J. Estimates of worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 54:1993;594-606.
58. Jin F., Devesa S.S., Chow W.H., et al. Cancer incidence trends in urban Shanghai, 1972-94: an update. Int J Cancer. 83:1999;435-440.
59. Munoz N., Day N. Esophageal Cancer. Schottenfeld D, Fraumeni JF. "Cancer epidemiology and prevention. 2nd edn :1996;Oxford University Press, New York, USA.